LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 1 | O20 | 72 | hr | 1476 | 2642 | 3788 | 0.6974 | 0.5341 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 2 | O20 | 72 | hr | 1476 | 2950 | 3731 | 0.7906 | 0.6778 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 3 | O20 | 72 | hr | 1476 | 2934 | 3796 | 0.7728 | 0.6552 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 1 | O19 | 72 | hr | 1476 | 2377 | 3788 | 0.6274 | 0.4194 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 2 | O19 | 72 | hr | 1476 | 2425 | 3731 | 0.6499 | 0.4491 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 3 | O19 | 72 | hr | 1476 | 2640 | 3796 | 0.6954 | 0.5318 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 1 | O18 | 72 | hr | 1476 | 3003 | 3788 | 0.7926 | 0.6857 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 2 | O18 | 72 | hr | 1476 | 3356 | 3731 | 0.8994 | 0.8476 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 3 | O18 | 72 | hr | 1476 | 3181 | 3796 | 0.8379 | 0.7564 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 1 | O17 | 72 | hr | 1476 | 2995 | 3788 | 0.7905 | 0.6824 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 2 | O17 | 72 | hr | 1476 | 3487 | 3731 | 0.9346 | 0.9013 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 3 | O17 | 72 | hr | 1476 | 3360 | 3796 | 0.8850 | 0.8284 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 1 | O16 | 72 | hr | 1476 | 3041 | 3788 | 0.8027 | 0.7014 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 2 | O16 | 72 | hr | 1476 | 3415 | 3731 | 0.9153 | 0.8718 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 3 | O16 | 72 | hr | 1476 | 3631 | 3796 | 0.9564 | 0.9356 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 1 | O15 | 72 | hr | 1476 | 3551 | 3788 | 0.9373 | 0.9069 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 2 | O15 | 72 | hr | 1476 | 3699 | 3731 | 0.9914 | 0.9871 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 3 | O15 | 72 | hr | 1476 | 3560 | 3796 | 0.9377 | 0.9077 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 1 | O14 | 72 | hr | 1476 | 3300 | 3788 | 0.8710 | 0.8068 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 2 | O14 | 72 | hr | 1476 | 3381 | 3731 | 0.9061 | 0.8579 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 3 | O14 | 72 | hr | 1476 | 3636 | 3796 | 0.9577 | 0.9375 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 1 | O13 | 72 | hr | 1476 | 2606 | 3788 | 0.6879 | 0.5187 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 2 | O13 | 72 | hr | 1476 | 2780 | 3731 | 0.7451 | 0.6049 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 3 | O13 | 72 | hr | 1476 | 2970 | 3796 | 0.7823 | 0.6701 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 1 | P12 | 72 | hr | 1476 | 3173 | 3788 | 0.8375 | 0.7554 |